Dotmatics, a leading provider of informatics solutions and services to the pharmaceutical and biotechnology industries, announced today that Progenra Inc. has decided to license their suite of scientific informatics solutions to boost

their research and development process.

Progenra is a biotechnology company dedicated to finding new medicines for a variety of diseases through the ubiquitin pathway. Progenra have replaced their conventional software provider with the progressive and integrated Dotmatics platform which allows their scientists to fully collaborate, maximize their use of data and reduce time to market decisions. Having evaluated other solutions, Progenra replaced legacy CambridgeSoft tools with the Dotmatics platform “because of the seamless interface and ease of use which has allowed Progenra to effectively and efficiently manage their internal and external programs,” commented Marc Hixson, Senior Director, Business Development,Progenra.

Dotmatics’ solutions are increasingly being chosen by the biotechnology and pharmaceutical industries to manage and analyze their critical scientific data.

Browser is an interactive query, reporting and dashboard which allows users to integrate and view complex research data from disparate sources. Biological assay data is seamlessly captured and analysed in Studies. With built-in chemistry awareness, Vortex provides a rich environment for predictive analytics, visualization and analysis of data. The Dotmatics platform is a fully optimized suite of programs designed to make research data readily accessible and useful.

About Progenra, Inc.

Founded in 2002, Progenra (www.progenra.com) seeks to discover and develop high value medicines exploiting ubiquitin

pathways. Utilizing its world-class UbiPro™ Drug Discovery Platform, Progenra identifies novel modulators of ubiquitin

targets as potential drugs exploiting the roles of ubiquitin in disease.